FluMist FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 2, 2024.
FDA Approved: Yes (First approved June 17, 2003)
Brand name: FluMist
Generic name: Influenza Virus Vaccine, Live, Intranasal
Dosage form: Nasal Spray
Company: MedImmune, Inc.
Treatment for: Influenza Prophylaxis
FluMist (influenza virus vaccine, live, intranasal) is a nasally administered vaccine intended for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
- FluMist is approved for use in persons 2 through 49 years of age.
Development timeline for FluMist
| Date | Article |
|---|---|
| Sep 20, 2024 | Approval FluMist Approved for Self-Administration in the US |
| Mar 1, 2012 | Approval FDA Approves FluMist Quadrivalent Vaccine to Prevent Seasonal Influenza |
| Sep 19, 2007 | Approval FDA Approves Expanded Label for FluMist to Include Children Two to Five Years of Age |
| May 16, 2007 | FDA Advisory Committee Recommends Expanded Use of FluMist |
| Jan 9, 2007 | Approval FDA Approves MedImmune's Refrigerated Formulation of FluMist |
| Jun 17, 2003 | Approval FDA Approves FluMist for Prevention of Influenza |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.